How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,702 results for

"Attention deficit hyperactivity disorder"

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. (Full text)

Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Attention deficit hyperactivity disorder (ADHD) in children is associated with hyperactivity and impulsivity, attention problems, and difficulties with social interactions. Pharmacological treatment may alleviate the symptoms of ADHD but this rarely solves difficulties with social interactions. Children with ADHD may benefit from interventions designed to improve their social skills. We (...) examined the benefits and harms of social skills training on social skills, emotional competencies, general behaviour, ADHD symptoms, performance in school of children with ADHD, and adverse events.To assess the beneficial and harmful effects of social skills training in children and adolescents with ADHD.In July 2018, we searched CENTRAL, MEDLINE, Embase, PsycINFO, 4 other databases and two trials registers.We also searched online conference abstracts, and contacted experts in the field

2019 Cochrane PubMed abstract

2. The transition from children's services to adult services for young people with attention deficit hyperactivity disorder: the CATCh-uS mixed-methods study (Full text)

The transition from children's services to adult services for young people with attention deficit hyperactivity disorder: the CATCh-uS mixed-methods study The transition from children's services to adult services for young people with attention deficit hyperactivity disorder: the CATCh-uS mixed-methods study Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please (...) choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This study found that few young people who need ongoing support for their ADHD successfully transfer to adult services, few experience optimal transitional care, and adult ADHD service provision is patchy. {{author}} {{($index , , , , , , , , , , , , , & . Astrid Janssens 1, 2 , Helen Eke 1 , Anna Price

2020 NIHR HTA programme PubMed abstract

3. Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. (Full text)

Cognitive-behavioural interventions for attention deficit hyperactivity disorder (ADHD) in adults. Attention deficit hyperactivity disorder (ADHD) is a developmental condition characterised by symptoms of inattention, hyperactivity and impulsivity, along with deficits in executive function, emotional regulation and motivation. The persistence of ADHD in adulthood is a serious clinical problem.ADHD significantly affects social interactions, study and employment performance.Previous studies (...) suggest that cognitive-behavioural therapy (CBT) could be effective in treating adults with ADHD, especially when combined with pharmacological treatment. CBT aims to change the thoughts and behaviours that reinforce harmful effects of the disorder by teaching people techniques to control the core symptoms. CBT also aims to help people cope with emotions, such as anxiety and depression, and to improve self-esteem.To assess the effects of cognitive-behavioural-based therapy for ADHD in adults.In June

2018 Cochrane PubMed abstract

4. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. (Full text)

Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies. Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in childhood. The psychostimulant methylphenidate is the most frequently used medication to treat it. Several studies have investigated the benefits of methylphenidate, showing possible favourable effects on ADHD symptoms, but the true magnitude (...) of the effect is unknown. Concerning adverse events associated with the treatment, our systematic review of randomised clinical trials (RCTs) demonstrated no increase in serious adverse events, but a high proportion of participants suffered a range of non-serious adverse events.To assess the adverse events associated with methylphenidate treatment for children and adolescents with ADHD in non-randomised studies.In January 2016, we searched CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL, 12 other databases

2018 Cochrane PubMed abstract

5. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. (Full text)

Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Attention deficit hyperactivity disorder (ADHD) is a childhood-onset disorder characterised by inattention, hyperactivity, and impulsivity. ADHD can persist into adulthood and can affects individuals' social and occupational functioning, as well as their quality of life and health. ADHD is frequently associated with other mental disorders such as substance use disorders and anxiety and affective disorders. Amphetamines (...) are used to treat adults with ADHD, but uncertainties about their efficacy and safety remain.To examine the efficacy and safety of amphetamines for adults with ADHD.In August 2017, we searched CENTRAL, MEDLINE, Embase, PsycINFO, 10 other databases, and two trials registers, and we ran citation searches for included studies. We also contacted the corresponding authors of all included studies, other experts in the field, and the pharmaceutical company, Shire, and we searched the reference lists

2018 Cochrane PubMed abstract

6. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. (Full text)

Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders. This is an update of the original Cochrane Review published in Issue 4, 2011.Attention deficit hyperactivity disorder (ADHD) is the most prevalent of the comorbid psychiatric disorders that complicate tic disorders. Medications commonly used to treat ADHD symptoms include stimulants such as methylphenidate and amphetamine; non-stimulants, such as atomoxetine; tricyclic (...) antidepressants; and alpha agonists. Alpha agonists are also used as a treatment for tics. Due to the impact of ADHD symptoms on the child with tic disorder, treatment of ADHD is often of greater priority than the medical management of tics. However, for many decades, clinicians have been reluctant to use stimulants to treat children with ADHD and tics for fear of worsening their tics.  OBJECTIVES: To assess the effects of pharmacological treatments for ADHD in children with comorbid tic disorders on symptoms

2018 Cochrane PubMed abstract

7. Attention deficit hyperactivity disorder: diagnosis and management

this guideline into practice 51 Context 53 More information 54 Update information 55 Attention deficit hyperactivity disorder: diagnosis and management (NG87) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 4 of 62This guideline replaces CG72 and TA98. This guideline is the basis of QS39. Ov Overview erview This guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder (ADHD) in children (...) , young people and adults. It aims to improve recognition and diagnosis, as well as the quality of care and support for people with ADHD. Who is it for? Healthcare professionals Commissioners and providers People with ADHD, and their families and carers Attention deficit hyperactivity disorder: diagnosis and management (NG87) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 5 of 62Recommendations Recommendations People

2018 National Institute for Health and Clinical Excellence - Clinical Guidelines

8. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. (Full text)

Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Attention deficit hyperactivity disorder (ADHD) is a prevalent neurobiological condition, characterised by behavioral and cognitive symptoms such as inattention, impulsivity and/or excessive activity. The syndrome is commonly accompanied by psychiatric comorbidities and is associated with educational and occupational underachievement.Although psychostimulant medications are the mainstay of treatment for ADHD, not all (...) adults respond optimally to, or can tolerate, these medicines. Thus, alternative non-stimulant treatment approaches for ADHD have been explored. One of these alternatives is bupropion, an aminoketone antidepressant and non-competitive antagonism of nicotinic acetylcholine receptors. Bupropion is registered for the treatment of depression and smoking cessation, but is also used off-label to treat ADHD.To assess the effects and safety of bupropion for the treatment of adults with ADHD.We searched

2017 Cochrane PubMed abstract

9. Crossing the divide: a longitudinal study of effective treatments for people with autism and attention deficit hyperactivity disorder across the lifespan (Full text)

Crossing the divide: a longitudinal study of effective treatments for people with autism and attention deficit hyperactivity disorder across the lifespan Crossing the divide: a longitudinal study of effective treatments for people with autism and attention deficit hyperactivity disorder across the lifespan Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please

2018 NIHR HTA programme PubMed abstract

10. Attention deficit hyperactivity disorder (ADHD): avoid guanfacine

Attention deficit hyperactivity disorder (ADHD): avoid guanfacine Prescrire IN ENGLISH - Spotlight ''Attention deficit hyperactivity disorder (ADHD): avoid guanfacine'', 1 October 2017 {1} {1} {1} | | > > > Attention deficit hyperactivity disorder (ADHD): avoid guanfacine Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Attention deficit (...) hyperactivity disorder (ADHD): avoid guanfacine In children diagnosed with attention deficit hyperactivity disorder (ADHD), guanfacine has no proven efficacy in improving family and social relationships. On the other hand, it has frequent, sometimes severe, adverse effects. In practice, it is best to avoid guanfacine. The diagnosis of attention deficit hyperactivity disorder in children is based on non-specific behavioural symptoms: inattentiveness, hyperactivity and impulsiveness. The disruptive impact

2017 Prescrire

11. Attention deficit hyperactivity disorder in adults

Attention deficit hyperactivity disorder in adults Attention deficit hyperactivity disorder in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Attention deficit hyperactivity disorder in adults Last reviewed: February 2019 Last updated: October 2018 Summary A common adult disorder, thought to be persistence of childhood attention deficit hyperactivity disorder (ADHD). Prevalence of 2% to 5% in the general (...) in combination with medication. Definition Adult attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder presenting with inattentiveness, impulsivity, and hyperactivity, persisting into adulthood. Diagnosis can be made in either adulthood or childhood by 7 years of age (age limit increased in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition [DSM-5] to 12 years). Functional impairment is a criterion for diagnosis. Comorbid disorders are present in more than 75

2018 BMJ Best Practice

12. Attention deficit hyperactivity disorder in adults

Attention deficit hyperactivity disorder in adults Attention deficit hyperactivity disorder in adults - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Attention deficit hyperactivity disorder in adults Last reviewed: February 2019 Last updated: October 2018 Summary A common adult disorder, thought to be persistence of childhood attention deficit hyperactivity disorder (ADHD). Prevalence of 2% to 5% in the general (...) in combination with medication. Definition Adult attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental disorder presenting with inattentiveness, impulsivity, and hyperactivity, persisting into adulthood. Diagnosis can be made in either adulthood or childhood by 7 years of age (age limit increased in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition [DSM-5] to 12 years). Functional impairment is a criterion for diagnosis. Comorbid disorders are present in more than 75

2018 BMJ Best Practice

13. Attention deficit hyperactivity disorder in children

of mental disorders, 5th ed., (DSM-5). Washington, DC: American Psychiatric Publishing; 2013. As a result, ADHD can limit academic, interpersonal, and occupational success and can also lead to greater risk-taking and accidents. Schonwald A, Lechner E. Attention deficit/hyperactivity disorder: complexities and controversies. Curr Opin Pediatr. 2006;18:189-195. http://www.ncbi.nlm.nih.gov/pubmed/16601502?tool=bestpractice.com In addition, patients with ADHD are more likely to have co-existing psychiatric (...) Attention deficit hyperactivity disorder in children Attention deficit hyperactivity disorder in children - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Attention deficit hyperactivity disorder in children Last reviewed: February 2019 Last updated: March 2018 Summary Common childhood-onset disorder characterised by inattention, hyperactivity, and/or impulsivity demonstrated across 2 or more settings (such as home

2018 BMJ Best Practice

14. Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward (Full text)

Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Twenty years of research on attention-deficit/hyperactivity disorder (ADHD): looking back, looking forward Article Text Clinical review Twenty years of research on attention

2018 Evidence-Based Mental Health PubMed abstract

15. Occupational therapy for attention-deficit/hyperactivity disorder (ADHD)

Occupational therapy for attention-deficit/hyperactivity disorder (ADHD) Occupational therapy for attention-deficit/hyperactivity disorder (ADHD) Occupational therapy for attention-deficit/hyperactivity disorder (ADHD) HAYES, Inc Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Occupational therapy for attention-deficit/hyperactivity disorder (ADHD (...) ) Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Occupational therapy (OT) for attention-deficit/hyperactivity disorder (ADHD) encompasses a wide array of interventions, with the aim of increasing function in all aspects of life and settings (school, home, etc.). Specific interventions vary and are determined by the occupational therapist depending on the presenting problems, deficits, and the therapist's determination of the best course of treatment. OT interventions for ADHD can

2017 Health Technology Assessment (HTA) Database.

16. Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

2014, four systematic reviews (including pairwise meta-analyses and network meta-analyses of direct and indirect evidence), one randomized controlled trial, and one guideline have been published regarding the use of guanfacine hydrochloride extended-release (GXR) for the treatment of attention deficit-hyperactivity disorder (ADHD) in children and adolescents.All included studies reported significant improvements in subjective ADHD rating scales as well as scales in executive function when using GXR (...) Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Guanfacine Hydrochloride Extended-Release for Attention Deficit Hyperactivity Disorder: A Review of Clinical Effectiveness, Cost

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

17. Guanfacine Hydrochloride Extended-Release for the Treatment of Attention Deficit Hyperactivity Disorder in Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

controlled trial suggested that guanfacine hydrochloride extended-release (GXR) was safe and well-tolerated when added to an existing psychostimulant treatment for adults with attention deficit hyperactivity disorder (ADHD). However, GXR did not differ from placebo with respect to clinical effectiveness. No evidence for the cost-effectiveness of GXR for the treatment of adults with ADHD was identified. One evidence-based guideline from the United Kingdom was identified that provides recommendations (...) Guanfacine Hydrochloride Extended-Release for the Treatment of Attention Deficit Hyperactivity Disorder in Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Guanfacine Hydrochloride Extended-Release for the Treatment of Attention Deficit Hyperactivity Disorder in Adults: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Guanfacine Hydrochloride Extended-Release for the Treatment of Attention Deficit

2018 Canadian Agency for Drugs and Technologies in Health - Rapid Review

18. Guanfacine (Intuniv) for attention deficit hyperactivity disorder (Full text)

a suboptimal response to stimulants. PBS listing Authority Required (Streamlined) On 1 March 2019, guanfacine (Intuniv) was listed on the PBS as an Authority Required (Streamlined) listing. It was listed as an adjunctive treatment to stimulant medicines in patients with attention deficit hyperactivity disorder (ADHD). , To receive subsidised treatment, patients must have residual moderate to severe symptoms despite receiving a maximum tolerated dose (MTD) of dexamfetamine, methylphenidate (...) submission for guanfacine are summarised below. ADHD-RS-IV: The Attention Deficit Hyperactivity Disorder Rating Scale IV is an investigator-rated questionnaire. It consists of 18 items that measure ADHD symptoms according to DSM-IV criteria. Scores range from 0 (never) to 54 (always). A between-group minimally clinically important difference (MCID) has not been fully established, but a 30% mean total score change (or 5.2–7.7 points) has been suggested in some publications. CGI-S: For the Clinical Global

2019 National Prescribing Service Limited (Australia) PubMed abstract

19. Squeeze balls for people with attention deficit hyperactivity disorder

Squeeze balls for people with attention deficit hyperactivity disorder Squeeze balls and fidget devices - Health Technology Wales > Squeeze balls and fidget devices Squeeze balls and fidget devices Topic Status Incomplete Squeeze balls for people with attention deficit hyperactivity disorder. Summary Health Technology Wales researchers searched for evidence on the effectiveness of squeeze balls or other fidget devices in adults with attention deficit hyperactivity disorder. Insufficient

2019 Health Technology Wales

20. Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research (Full text)

Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD)delivered in school settings: systematic reviews of quantitative and qualitative research Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page

2015 NIHR HTA programme PubMed abstract